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Mice immunized against 
 
Mycobacterium tuberculosis
 
 (Mtb) infection by curing them of a 
primary lung infection were compared with naive mice in terms of the ability to generate a 
Th1 cell immune response and to control growth of an airborne Mtb challenge infection. 
Immunized mice generated and expressed Th1 cell immunity several days sooner than naive 
mice, as demonstrated by an earlier increase in the synthesis in the lungs of mRNA for Th1 
cytokines and for inducible nitric oxide synthase, an indicator of macrophage activation. This 
Th1 cytokine/mRNA synthesis was accompanied by an earlier accumulation of Mtb-specific 
Th1 cells in the lungs and the presence of CD4 T cells in lesions. An earlier generation of 
immunity was associated with an earlier inhibition of Mtb growth when infection was at a 
1-log lower level. However, inhibition of Mtb growth in immunized, as well as in naive, mice 
was not followed by resolution of the infection, but by stabilization of the infection at a 
stationary level. The results indicate that there is no reason to believe that the secondary 
response to an Mtb infection is quantitatively or qualitatively superior to the primary response.
 
Tuberculosis is a major world disease esti-
mated to kill more than two million people
annually (1). This is the case even though only
5–10% of immunocompetent humans are sus-
ceptible, presumably because of an inability to
mount a successful immune response against
 
Mycobacterium tuberculosis
 
 (Mtb), the causative
agent of the disease. It is generally believed
that this deficiency in susceptible humans can
be overcome by vaccination. However, the
only approved vaccine currently available, the
attenuated bacillus Calmette-Guerin (BCG)
strain of 
 
M. bovis
 
, has proved unreliable for
this purpose (2). Consequently, research in
many laboratories is aimed at developing a
vaccine that is more effective than BCG. It is
known (3, 4) that immunity to tuberculosis is
mediated predominantly by Th1 cells, with
the aid of CD8 T cells, and is expressed by ac-
tivated macrophages in which Mtb resides at
infectious foci. We have recently argued (4)
that mouse tuberculosis may be considered a
model of tuberculosis in susceptible humans;
in mice, as in 
 
 
 
85% of immunocompetent
susceptible humans (5), tuberculosis is a disease
exclusively of the lungs. On the other hand,
in immunocompromised mice and humans,
the disease is systemic and can involve multiple
organs. This is the situation in humans immu-
nocompromised by HIV infection (6) or other
means (7), and it is the situation in mice that
have been functionally deleted of genes required
for the production of Th1 cells or cytokines
(8). Therefore, it is apparent that both host
species respond to Mtb infections by acquiring
a level of immunity that is capable of protect-
ing all organs, except the lungs, from progres-
sive disease. 
In this regard, it is known (9) that Mtb-
infected mice generate a Th1 cell immune re-
sponse that is capable of inhibiting further
Mtb growth in the lungs at about day 20 of
infection and of holding the infection at an
approximate stationary level from that time
on. However, stationary lung infections in
mice cause a progressive lung pathology that is
eventually lethal (4). Therefore, in order to be
successful in this host species, immunity
would need to be capable of causing a lung
infection to completely resolve, or resolve to a
level incapable of inducing pathology. Sus-
ceptible humans with active diseases may also
be considered capable of acquiring the capac-
ity to restrict the growth of Mtb; otherwise,
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they would succumb to an infection as early as immuno-
compromised humans. In support of this proposition, it is
known that humans with active pulmonary tuberculosis
generate an Mtb-specific Th1 cell immune response, as evi-
denced by an acquired ability to express delayed-type sensi-
tivity to intracutaneously injected Mtb antigens (10, 11) and
by the acquisition of CD4 and CD8 T cells capable of re-
sponding to Mtb antigens in vitro (12–14). Presumably, the
purpose of vaccination is to ensure that enough of these T
cells are generated in response to an infection to cause it to
resolve. It is apparent, however, that attempts to achieve
this in mice with a variety of recently developed vaccines
have been unsuccessful, so that the protection afforded by
them has been no better, or only marginally so, than that af-
forded by BCG. It has been the general finding (15) that
vaccination with recently designed vaccines, like vaccina-
tion with BCG, enables mice to reduce the level of an Mtb
lung infection by 
 
 
 
1 log. However, the immunologic sig-
nificance of 1 log of protection appears not to have been
fully investigated.
This paper will show that, according to the levels of
Th1 cytokine gene transcription and the amount of CD4
Th1 cells generated, mice immunized by curing them of a
primary airborne Mtb infection generate Th1 cell immunity
to an airborne challenge infection sooner than naive mice,
thereby enabling them to inhibit Mtb growth earlier, but
not to resolve the infection. The results provide no reason
to believe that the secondary response, although generated
earlier, is qualitatively or quantitatively superior to the pri-
mary response.
 
RESULTS
Earlier inhibition of Mtb growth in immunized mice
 
The ability of mice cured of a primary airborne Mtb infection
to deal with a secondary airborne infection with the same
strain of Mtb is shown in Fig. 1. It can be seen that Mtb grew
at the same rate (doubling time 
 
  
 
28 h) in the lungs of im-
munized and naive mice for about the first 15 d of infection,
after which further Mtb growth was inhibited in the lungs of
immunized, but not of naive, mice. In the latter, Mtb growth
was not inhibited until about day 20. Thus, immunized mice
were able to shorten the period of progressive Mtb growth by
the equivalent of approximately four Mtb doubling times,
which corresponds to about a 1-log lower level of infection.
In immunized and naive mice, the levels of infection re-
mained approximately stable after Mtb growth was inhibited.
This result was obtained in two separate experiments. Thus,
according to Fig. 1, immunized, like naive, mice showed no
ability to immediately reduce the number of Mtb bacilli that
implanted in the lungs, to slow the initial rate of Mtb growth,
or to cause an established Mtb infection to resolve.
 
Earlier increases in Th1 cytokine gene transcription in 
immunized mice
 
A previous study (9) showed that control of Mtb growth in
the lungs of naive mice occurs at about day 20 of infection
Figure 1. Course of Mtb infection in the lungs of immunized and 
naive mice infected with  2   102 CFUs of Mtb via the airborne 
route. Mtb grew log linearly for  20 d in the lungs of naive mice and for 
15 d in the lungs of immunized mice before further growth was inhibited. 
Both in naive and immunized mice, inhibition of Mtb growth was followed 
by a stationary level infection that was 1 log lower in immunized mice. 
Means   SD of five mice per group.
Figure 2. Real-time RT-PCR quantification of changes in Th1 cytokine 
gene transcription in the lungs of naive and immunized mice. Large 
increases in the synthesis of mRNA for IL-2, IFN- , and TNF-  were evi-
dent by day 12 of infection in immunized mice, 4 d earlier than in naive 
mice. The same applied to the increased synthesis of mRNA for IP-10 and 
MCP-10, and for NOS2. After day 12 in immunized and day 16 in naive 
mice, mRNA synthesis continued to increase to peak at 1–3 log higher 
levels, depending on the particular mRNA. Peak levels of synthesis were 
reached earlier in immunized mice, but were no higher than in naive mice. 
In all cases, mRNA synthesis was sustained at high levels until day 50, 
when the experiment was terminated. The results were obtained with the 
pooled lung RNA of four mice per time point per group. Shown are the 
means and SDs of four separate readings. The experiment was performed 
twice with essentially the same result. 
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and is dependent on the ability to generate Th1 cell immu-
nity. It was anticipated, therefore, that an earlier control of
lung infection by immunized mice would be associated with
an earlier generation and expression of Th1 cell immunity.
This was initially investigated by quantifying changes against
time of infection in the levels of expression of Th1 cytokine
genes with real-time RT-PCR. The results in Fig. 2 clearly
show that an increased synthesis of mRNA for IL-2, IFN-
 
 
 
,
and TNF-
 
 
 
 was initiated several days earlier and reached
higher levels sooner in the lungs of immunized mice than in
the lungs of naive mice. The same applied to an increased
synthesis of mRNA for chemokines, IP-10, and MCP-1,
and to an increased synthesis of mRNA for inducible nitric
oxide synthase (NOS2), an indicator of IFN-
 
 
 
–induced
transcriptional activation of macrophages (16). According to
the levels of IFN-
 
 
 
 and NOS2 gene transcription, the mag-
nitude of the secondary response was somewhat lower,
rather than higher, than that of the primary response at day
30. In both cases, the synthesis of Th1 cytokines and NOS2
mRNAs was sustained at high levels until the experiment
was terminated at day 50. It will be noted in Fig. 2 that, al-
though the levels of Th1 cytokine/mRNA synthesis were
higher in the lungs of immunized mice before the challenge
infection was given, an increased synthesis of these mRNAs
did not take place in response to an infection in mice of ei-
ther group until after an appreciable delay.
 
Earlier increase in the number of IFN-
 
 
 
–producing CD4 T 
cells in immunized mice according to flow cytometry
 
To determine whether earlier generation of immunity in
immunized mice, as evidenced by earlier increases in the ex-
pression of Th1 cytokine genes in the lungs, is associated
with the earlier increase in the number Th1 cells, flow cy-
tometry was used to measure changes against time in the
number of IFN-
 
 
 
–producing CD4 cells. Fig. 3 shows that in
both naive and immunized mice, an infection resulted in an
increase in the total number of CD4 T cells in the lungs, and
that these cells increased in number sooner in the lungs of
immunized mice. Peak accumulation of CD4 T cells oc-
curred on day 18 in the lungs of these mice and on day 30 in
the lungs of naive mice, resulting in a higher peak number in
the lungs of the latter. These numbers were approximately
sustained until the experiment was terminated on day 85.
The same results were obtained in two separate experiments.
According to Fig. 3, IFN-
 
 
 
–producing CD4 cells were
not present in large numbers in the lungs of immunized or
naive mice on day 9 of infection, but began accumulating in
the lungs of the former between days 9 and 12 and in the lat-
ter between days 12 and 15. Peak accumulation occurred on
day 20 in immunized mice and on day 30 in naive mice. It
will be noted in Figs. 3 and 4 that 
 
 
 
10% of the CD4 T cells
were making IFN-
 
 
 
 at any one time of infection. According
to Fig. 5, the majority of the gated IFN-
 
 
 
–producing CD4
cells displayed the CD44
 
hi
 
 CD62L
 
low
 
 activation phenotype.
It is assumed that the majority of cells making IFN-
 
 
 
, ac-
cording to flow cytometry, were making this cytokine in re-
sponse to an infection at the time of cell harvest. The pres-
ence of ESAT-6 peptide during the 5-h incubation period
with brefeldin A had little or no effect on the number of
cells synthesizing IFN-
 
 
 
 (unpublished data).
Figure 3. The results of a flow cytometry analysis of the number of 
CD4 T cells and IFN- –secreting CD4 T cells that accumulated in 
the lungs of naive and immunized mice against time of the challenge 
infection. CD4 T cells began accumulating earlier in immunized mice and 
reached peak numbers on day 20, after which the number remained rela-
tively constant. In naive mice, the peak number was reached on day 30. 
The same kinetics applied to the accumulation of IFN- –producing CD4 T 
cells in the naive and immunized mice, except that only a small percentage 
of the CD4 cells were positive for IFN- . The results were obtained with 
pooled lung cells from four mice stained for surface CD4 and intracellular 
IFN-  as described in Materials and methods. The same result was obtained 
in two separate experiments.
Figure 4. Only a small percentage of CD4 T cells were making 
IFN-  at peak responses. Only 10.5% of CD4 T cells in the lungs of naive 
mice (day 30), and 8.35% in the lungs of immunized mice (day 20), were 
making IFN-  according to flow cytometry. The results were obtained with 
pooled lung cells of four mice stained for surface CD3 and CD4 and for 
intracellular IFN-  as described in Materials and methods. 
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Earlier increase in the number of Mtb-specific CD4 T cells in 
the lungs of immunized mice as enumerated by Elispot
 
The generation kinetics of Th1 cells specific to Mtb were
determined with the Elispot assay. Fig. 6 shows that cells ca-
pable of making IFN-
 
 
 
 in response to ESAT-6
 
1-20
 
 peptide,
to Ag85B
 
240-254
 
 peptide, or to antigens present in the Mtb
sonicate accumulated and reached peak numbers sooner in
the lungs of immunized mice. In these mice, cells capable of
making IFN-
 
 
 
 in response to the previously mentioned anti-
gen preparations were present in an increased number in the
lungs by day 12 of infection and continued to increase in
number until day 20, after which their number approxi-
mately stabilized. In contrast, in the lungs of naive mice, cells
capable of making IFN-
 
 
 
 in response to these antigens were
not present in increased numbers until day 18, after which
they continued to increase until day 30 and then slowly de-
clined. Consequently, the production of T cells capable of
making IFN-
 
 
 
 in response to Mtb antigens reached greater
numbers in the lungs of naive mice. The number of cells that
responded to ESAT-6 in the lungs of naive and immunized
mice was not much smaller than the number that responded
to antigens in the Mtb sonicate. This result was obtained in
two separate experiments. If one assumes that the Mtb soni-
cate contained enough ESAT-6 to stimulate all ESAT-6–
specific T cells, it would follow that a large proportion of the
Mtb-specific T cells present in the lungs were generated
against this particular antigen. This finding would be in
keeping with the demonstration of Brandt et al. (17) that
ESAT-6 is a dominant Th1 cell antigen in mice.
Fig. 6 also shows that several lung cells made IFN-
 
 
 
 in
the absence of added antigen, and that these cells accumu-
lated with kinetics similar to those that were antigen specific.
It seems reasonable to suspect that they were making IFN-
 
 
 
in response to Mtb antigens at the time of cell harvest and
that they continued to do so in the assay. It is likely that
IFN-
 
 
 
 made in the absence of added antigen was in response
to the presence of viable Mtb in the lung cell suspension.
That viable intracellular Mtb was present is evidenced by the
results of an experiment that determined the number of Mtb
CFUs present in positively selected CD11b cells from pooled
lung cells of four naive mice harvested on day 30 of infec-
tion, as described in Materials and methods. It was found that
one lung equivalent of positively selected CD11b cells
(2.3 
 
 
 
 10
 
6
 
 cells) contained 10
 
6.19
 
 CFUs of Mtb. In contrast,
the lung cell suspension depleted of CD11b cells contained
only 10
 
4.2
 
 CFUs of Mtb. Thus, in the in vitro assays used, a po-
tential antigen was present in the form of viable intracellular
Mtb. It is assumed that this also applied to lung cells obtained
Figure 5. IFN- –producing CD4 T cells in the lungs displayed an 
activation phenotype. The majority of the CD4 T cells making IFN-  in 
naive and vaccinated mice in response to a challenge infection displayed 
the CD44hiCD62Llow activation surface phenotype. Cells were stained for 
surface CD4, CD62L, and CD44, and intracellular IFN-  as described in 
Materials and methods.
Figure 6. Kinetics of accumulation of Mtb-specific T cells in the 
lungs of naive and immunized mice. T cells capable of synthesizing IFN-  in 
response to exposure to ESAT-61-20 peptide, Ag85240-254 peptide, and Mtb 
sonicate were enumerated with the Elispot assay. Increased numbers of 
Mtb-specific T cells were present in the lungs of immunized mice by day 
12 of infection, but not until day 18 in the lungs of naive mice. Mtb-specific 
cells increased to peak on day 21 in the case of immunized mice and on 
day 30 in the case of naive mice. Consequently, Mtb-specific cells accu-
mulated in higher numbers in the lungs of the latter mice. Results were 
obtained with pooled lung cells from four mice. Shown are the means   
SD of the number of spots in triplicate wells. The same result was obtained 
in two separate experiments. 
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from immunized mice. The result is not surprising given that
no attempt was made to remove macrophages from the cell
suspensions used for in vitro assays. This will be the subject
of a future publication from this laboratory.
Because the ESAT-6
 
1-20 
 
and Ag85B
 
240-254
 
 peptides are
Class II (IA
 
b
 
) presented, it is reasonable to conclude that the
cells that made IFN-
 
 
 
 in response to them were CD4 T
cells. This was confirmed by the results of an Elispot assay
performed with lung cell suspensions magnetically depleted
of 
 
 
 
90% CD4 cells. It can be seen in Fig. 7 that removing
CD4 T cells from the lung cell suspension harvested on day
30 from naive mice and on day 20 from immunized mice re-
moved most of the cells capable of making IFN-
 
 
 
 in re-
sponse to ESAT-6, Ag85B, and the Mtb sonicate. The con-
tribution of different T cell subsets to immunity is the
subject of a study currently in progress in this laboratory.
 
Location of CD4 cells in lesions
 
Our results show that the expression of Th1 cell–mediated
immunity to an Mtb infection was associated with an appre-
ciable increase in the number of CD4 T cells in the lungs. To
mediate immunity, these cells would need to be located at
sites of infection in the lungs where Mtb resides in macro-
phages. To determine the location of CD4 cells, immunocy-
tochemistry was performed on lung sections using anti-CD4
mAb as a primary reagent. Fig. 8 shows that each site of in-
fection (lesion) in naive mice on day 30 and in immunized
mice on day 20 consisted of a region of alveolitis populated
almost exclusively by mononuclear cells. Groups of air sacs
Figure 7. Evidence that the majority of cells that made IFN-  in 
the Elispot assay were CD4 positive. Magnetic depletion of  90% 
CD4 T cells from the lung cell suspension resulted in the removal of the 
majority of cells capable of making IFN-  in response to ESAT-61-20 
peptide, to Ag85B240-254 peptide, or to the Mtb sonicate in the Elispot 
assay. The experiment was performed with pooled cells harvested from 
four immunized mice on day 20 and from four naive mice on day 31 
of infection.
Figure 8. Immunocytochemical demonstration of CD4 cells in lung 
lesions of immunized and naive mice at the peak of CD4 cell accu-
mulation. 40  micrographs of lung lesion of a 30-d-infected naive mouse 
(a) and a 21-d-infected immunized mouse (c) showing CD4-positive cells 
(dark brown) throughout the lesion. 100  micrographs of a lesion of a 
naive (b) and immunized mouse (d) showing some CD4-positive cells in 
proximity to macrophages containing acid-fast bacilli. Discrete black/
brown smudges represent CD4-positive cells out of the plane of focus. 
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scattered throughout each lesion contained Mtb-infected
macrophages. Cells that stained for surface CD4 were present
in relatively large numbers throughout each lesion in the in-
terstitium and to a lesser extent in air sacs containing infected
macrophages. CD4 cells were also present around veins and
arteries in close proximity to lesions. Given that lesions did
not exist before the infection was initiated, the relatively large
number of lesion-based CD4 cells would account for a large
proportion of the increased number of CD4 cells that accu-
mulated in the lungs in response to infection.
 
DISCUSSION
 
This paper shows that mice immunized against an Mtb in-
fection by curing them of a primary lung infection acquired
a capacity to generate Th1 cell immunity to an airborne Mtb
challenge infection sooner than unimmunized mice. Earlier
generation of Th1 cell immunity was associated with an ear-
lier inhibition of Mtb growth when the number of CFUs in
the lungs was 
 
 
 
1 log lower. On the other hand, immunized
mice were unable to immediately kill Mtb bacilli that im-
planted in the lungs, cause Mtb infection to progress at a
slower initial rate, or cause the infection to resolve. Instead,
they were able to hold infection at a lower stationary level
from day 15 on. Thus, the protection afforded by immuniza-
tion was wholly attributable to an earlier inhibition of Mtb
growth. In the apparent absence of any evidence to the con-
trary, it is reasonable to propose that the protection afforded
mice by vaccinating them with BCG, or any one of several
recently designed vaccines, will also prove to be wholly at-
tributable to an ability to inhibit Mtb growth during an ear-
lier stage of infection. It is predicted that this will also be
found to apply to any marginal increase in the level of pro-
tection afforded by one vaccine over another, or by giving
booster injections of a particular vaccine. It needs to be
noted that shortening the period of progressive Mtb growth
by the equivalent of one Mtb doubling time (28 h) would
enable a vaccine to reduce the level of stationary infection by
 
 
 
50%. The finding that the pathogen grew at the same rate
in immunized and naive mice for the first 12–15 d of infec-
tion is in accordance with results obtained with guinea pigs
(18) and mice (19). The reason for the exceptionally long
delay in immunized, as well as naive, mice before anti-Mtb
immunity is expressed in the lungs remains unknown.
The earlier generation and expression of Th1 cell immu-
nity by Mtb-immunized mice was measured here in terms of
an earlier increase in the synthesis in the lungs of mRNA for
the Th1 cytokines (IL-2, IFN-
 
 
 
, and TNF-
 
 
 
) and in the
synthesis of mRNA for NOS2, an inducible enzyme of mac-
rophages that signifies a transcriptional response that results
in up-regulation of their antimycobacterial function (16). It
was also associated with earlier increases in the synthesis of
mRNA for the chemokines (IP-10 and MCP-1), indicating
that an earlier expression of secondary immunity was associ-
ated with an earlier inflammatory response. The earlier gen-
eration of Th1 cell immunity in immunized mice was also
evidenced by the earlier appearance and accumulation of
Mtb-specific T cells in the lungs. Thus, cells capable of mak-
ing IFN-
 
 
 
 in response to Mtb antigens, as enumerated in the
Elispot assay, increased in number between days 12 and 20
in the lungs of immunized mice and between days 18 and 30
in the lungs of naive mice. Immunocytochemistry revealed
that many of these cells were present in lesions.
The finding that a large proportion of Mtb-specific cells
generated in the primary and secondary responses were spe-
cific for the ESAT-6
 
1-20
 
 peptide is in keeping with the con-
clusion of Brandt et al. (17) that this secreted protein is a ma-
jor Mtb antigen in mice. ESAT-6 has also been shown to be
a major Mtb antigen in humans (20) and cattle (21). Because
the ESAT-6
 
1-20
 
 and Ag85B
 
240-254
 
 peptides are MHC Class II
(IA
 
b
 
) presented, it follows that the ESAT-6– and Ag85B-
specific cells enumerated were CD4 T cells. This was con-
firmed by the additional finding that depleting CD4 T cells
from the lung cell suspension removed the majority of cells
capable of making IFN-
 
 
 
 in response to these peptides. In
spite of the high frequency of ESAT-6–specific T cells made
in the primary and secondary responses, however, there is no
compelling reason to believe that T cells specific for this an-
tigen were necessary for the anti-Mtb primary or secondary
response to be protective. It is apparent from the literature
(15) that the level of protection afforded mice by vaccinating
them with an ESAT-6–expressing DNA vaccine is no better
than that afforded by vaccinating them with DNA vaccines
expressing Ag85A or Ag85B, or with BCG. Moreover, be-
cause it was shown by Schell et al. (19) some years ago, and
more recently by others (22), that vaccination with BCG is
no more protective than vaccinating with Mtb itself, it is
reasonable to propose that the limited protective value of
BCG is not a consequence of its inability to make ESAT-6
and other Mtb antigens encoded by genes known to be ab-
sent from BCG (23). Again, the level of protection afforded
mice by immunizing them via the respiratory route with
Mtb, as reported here, is similar to the level that has been re-
ported by others for mice vaccinated with BCG via the i.v.
route (15), indicating that vaccination via the respiratory
route does not offer any protective advantage. This is in
keeping with the early findings of Schell et al. (19) and the
more recent findings of others (24, 25). 
Moreover, an important point to make about vaccination
via the airborne route with live BCG or Mtb is that in order
to avoid the complexity of superimposing one infection on
another, it is necessary to cure the immunizing lung infection
before giving the challenge infection. This is not always
done. It is known that a lung infection with BCG (19, 23),
like lung infections with virulent (9) or avirulent Mtb (26),
persists at an approximately stationary level for a protracted
period of time. It is also known (26) that the maintenance of
a stationary level of lung infection with virulent or avirulent
Mtb is associated with an ongoing, active Th1 response, as
evidenced by a sustained increase in the level of Th1 cyto-
kine gene transcription. The influence of persistent BCG in- 
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fection on the level of immunity to an Mtb challenge infec-
tion was recently shown to be considerable (27), presumably
because it provides the antigenic stimulus for maintaining
immunity in an active state. In this study, the immunizing
Mtb lung infection was terminated by 100 d of chemother-
apy before the secondary infection was initiated. Therefore,
the response to the secondary infection may be considered an
active secondary response, a conclusion supported by the
finding that it was not expressed until after a delay of 
 
 
 
15 d.
We are aware, as shown many years ago (28), that in spite of
the apparent absence of viable Mtb in mouse tissues after
long-term chemotherapy, some viable bacilli remain present
in a latent state. Initiating an Mtb infection via the respira-
tory route followed by curing the infection with chemother-
apy almost certainly will not be used as a means to vaccinate
humans against tuberculosis. Nevertheless, this method of
vaccination is performed each time a susceptible human with
tuberculosis is treated successfully with chemotherapy. Ac-
cording to recent studies (29, 30), however, humans cured of
the active disease by chemotherapy can become exogenously
reinfected with different strains of Mtb within weeks. This
would indicate that, in the case of at least a proportion of
susceptible humans, a successful vaccination against tubercu-
losis will be difficult to achieve.
It should be noted that this study deals with the response
to infections in the lung, the only mouse organ in which an
Mtb infection causes progressive disease (4). However, it is
generally accepted that primary and secondary immune re-
sponses to infectious agents are initiated in draining lymph
nodes. Presumably, therefore, the earlier increase in the
number of Mtb-specific T cells in the lungs of immunized
mice was a reflection of an earlier production of these cells in
the draining nodes and their earlier release into the circula-
tion from which they entered the lungs at sites of infection.
This aspect of the anti-Mtb response is currently under study
in this laboratory. Results obtained thus far (unpublished data)
indicate that the number of Mtb-specific T cells in the drain-
ing node at any one time of infection is considerably smaller
than the number in the lungs. Moreover, because it has been
demonstrated (31) that Mtb-specific Th1 cells in the lungs be-
long to a replicating population, it is likely that most of them
are generated locally in response to antigens presented by in-
fected macrophages. The interpretation that the continuous
expression of active Th1 cell immunity is responsible for hold-
ing an infection at a stationary level is supported by the
knowledge (32) that depleting mice with a stationary lung in-
fection of CD4 cells results in a resumption of Mtb growth.
This study does not show why the secondary and pri-
mary immune responses, although capable of stabilizing an
infection at a stationary level, were not capable of causing
the infection to resolve. However, because it shows that
there is no reason to believe that the secondary response is
quantitatively or qualitatively superior to the primary re-
sponse, it seems obvious that the secondary response failed to
resolve the infection for the same reason as the primary re-
sponse. Because macrophages are the cells that express im-
munity, the failure to resolve the infection was presumably
the result of the failure of macrophages to acquire an ade-
quate antimicrobial function. On the other hand, it is possi-
ble that the inhibition of Mtb growth, as evidenced by a sta-
tionary level infection, is initiated by the pathogen itself as
part of a counterresponse to the acquired antimycobacterial
function of macrophages. It has been demonstrated (33), in
this regard, that the ingestion of Mtb by activated macro-
phages causes a dramatic transcriptional response on the part
of the pathogen that results in its acquiring a “dormancy
transcriptome” that likely enables it to survive host adaptive
defenses. Mtb has been shown (33) to undergo a similar
transcriptional response in the lungs of mice at the time of
expression of adaptive immunity. It is therefore possible that,
in vaccinated mice, the activation of macrophages by an ear-
lier generation of Th1 cells merely serves to trigger an earlier
protective transcriptional response on the part of the patho-
gen. Until it is shown that the secondary anti-Mtb response
is quantitatively and qualitatively superior to the primary re-
sponse and causes macrophages to acquire a higher level of
antimycobacterial function, there is no reason to believe that
vaccination should enable mice to resolve an infection.
As for the survival consequences of infection levels 
 
 
 
1
log lower in Mtb-immunized mice, it almost certainly
would result in a longer time of survival. It was shown by
Wiegeshaus et al. (34) that BCG vaccination enables guinea
pigs to hold infection at a level 
 
 
 
2 log lower than naive
guinea pigs and to survive for about twice as long from a
small airborne Mtb challenge infection. It also has been
shown (35) that BCG vaccination of mice of the genetically
susceptible DBA/2 strain enabled them to survive approxi-
mately twice as long as naive DBA/2 mice from an Mtb
challenge given via the i.v. route. The same study showed
that naive mice of the genetically resistant BALB/c strain all
died from an i.v. Mtb challenge infection before any BCG-
vaccinated BALB/c mice died. It is apparent that although
vaccination provides guinea pigs and mice the ability to sta-
bilize and hold an Mtb challenge infection at a lower station-
ary level, a lower level of infection nevertheless induces the
development of progressive, lethal lung pathology.
 
MATERIALS AND METHODS
 
Mice. 
 
C57BL/6 male mice were purchased from The Jackson Laboratory
and were 12 wk old when used in experiments. The experiments were per-
formed and the mice were housed under barrier conditions in a Level III
Biosafety Animal Facility in accordance with guidelines formulated by the
Trudeau Institute Animal Care and Use Committee.
 
Immunization and infection.
 
The H37Rv strain of Mtb (Trudeau My-
cobacterial Culture Collection, no. 102) was grown in a suspension culture
in Proskauer and Beck medium containing 0.01% Tween 80 and harvested
during log-phase growth, as described previously (36). The culture was sub-
jected to two 5-s bursts of ultrasound to break up clumps and appropriately
diluted in PBS containing 0.01% Tween 80 for infection via the respiratory
route in an aerosol infection chamber, as described previously (9). Mice
were immunized by infecting them via the respiratory route with 
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CFUs of H37Rv, allowing the infection to proceed for 30 d, and then
treating them for 100 d with 0.3 mg isoniazid and 0.1 mg rifampin (Sigma-
Aldrich) per milliliter in drinking water. This study shows that the primary
Th1 response to lung infection with H37Rv peaks on about day 30. At the
end of chemotherapy, the lungs were considered free of viable Mtb as
judged by the absence in lung homogenates of Mtb capable of forming col-
onies on nutrient agar. Immunized and naive mice were challenged at the
same time in the same aerosol infection chamber with 
 
 
 
2 
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2
 
 CFUs of
H37Rv. The lung infection was monitored by measuring changes against
time in the total number of CFUs in the lungs. This involved killing five
mice at the times indicated, homogenizing the lungs, plating serial dilutions
of lung homogenates on enriched Middlebrook 7H11 agar, and counting
colonies after incubating the plates for 21 d at 37
 
 
 
C.
Mtb antigens. The Mtb antigens used to stimulate IFN-  production by
lung cells were Esat-61-20 peptide (17), Ag85B240-254 peptide (37), and an ul-
trasound-disrupted H37Rv culture. Both peptides were purchased from
New England Peptide. ESAT-6 is a secreted Mtb protein of unknown
function (17), whereas Ag85B is a member of a family of mycolyl trans-
ferases involved in cell wall lipid biosynthesis (37). The Mtb sonicate was
prepared by subjecting a culture of H37Rv (2   108 CFUs/ml in Proskauer
and Beck medium) at 10 C to 5 min of ultrasound generated by a sonicator
(model 1510; Braun-Sonic) set at 400 W. Because Proskauer and Beck me-
dium is composed of inorganic salts and glycerol, all antigens present in the
Mtb sonicate were derived from Mtb.
Lung cell preparation.  To harvest lung cells, mice were killed by cervi-
cal dislocation, and their lungs were perfused via the right ventricle with
PBS containing 10 U/ml heparin to remove intravascular leukocytes. The
lungs were then perfused with an enzyme cocktail consisting of 150 U/ml col-
lagenase, 0.2 U/ml elastase (Roche), and 1 mg/ml DNase (Sigma-Aldrich)
in RPMI 1640. The lungs were removed, placed in a dish, and diced into
small fragments, and the fragments were incubated in the enzyme mixture
at 37 C for 1 h. The preparation was passed through a 60-mesh/in2 stainless
screen, and the resulting suspension was triturated with a pipette to break
up aggregates. The cells were pelleted and resuspended in red cell lysis
buffer (Sigma-Aldrich). They were then washed, passed through a 70- m
nylon cell strainer (BD Biosciences), pelleted, and resuspended in RPMI
1640 with 10% FCS (RPMI-FCS) for counting and analysis.
Cell depletion.  Lung cell suspensions were selectively depleted of CD4
or CD11b cells magnetically. This involved incubating the cell suspension
with 10  g/ml of biotin-conjugated anti-CD4 or anti-CD11b rat anti–
mouse mAbs (BD Biosciences) for 40 min at 4 C. The cells were washed
twice with buffered PBS containing 0.5% BSA, pelleted, and resuspended
in 0.1 ml of buffered PBS containing streptavidin-coupled magnetic nano-
particles (IMag Streptavidin Particles; BD Biosciences) according to the
manufacturer’s instructions. The cells were placed in a 5-ml tube that was
inserted into a close-fitting Perspex tube holder with a recess containing a
45   35-mm neodynium-iron-boron magnet (ForceField). After 6 min at
10 C, cells not held magnetically to the side of the tubes were removed
with a pipette. The procedure was repeated three times, after which the de-
pleted cells and the magnetically enriched cells were pelleted and resus-
pended for analysis by flow cytometry and Elispot. The procedure resulted
in  90% depletion of CD4 T cells. Part of the enriched CD11b cell sus-
pension was subjected to 5 s of ultrasound to cause cell disruption and was
then 10-fold serially diluted in Tween 80–PBS. The dilutions were plated
on nutrient agar and after an 18-d incubation at 37 C, CFUs of Mtb were
counted with the aid of a dissecting microscope.
BM-derived DCs.  These were generated from C57BL/6 BM according
to a published procedure (38). A GM-CSF–expressing J558L cell line (sup-
plied by I. Mellman, Yale University School of Medicine, New Haven, CT)
was used as a source of GM-CSF. The DCs were generated in large numbers
and distributed in 1-ml lots each containing 2   106 cells. They were frozen
and stored at  150 C in RPMI 1640 with 20% FCS and 10% DMSO. For
experiments, the cells were thawed, washed, and resuspended in RPMI-FCS.
Elispot.  Changes in numbers of Mtb-specific cells in the lungs against time
of infection were determined by enumerating changes in the numbers of
cells capable of making IFN-  in response to Mtb antigens in the Elispot as-
say. This was performed with a commercially available Elispot kit (Mouse
IFN-  ELISPOT Set; BD Biosciences) according to the manufacturer’s in-
structions using pooled cells from four mice. It involved coating 96-well ni-
trocellulose plates with a rat anti–mouse IFN-  mAb, washing with RPMI,
and blocking with RPMI-FCS. To supplement APCs already present in the
lung cell suspension, BM-derived DCs were added to the cell suspension at a
ratio of 5:1 lung cells/DC. Twofold serial dilutions of the 100- l admixture
were added in triplicate to the wells starting at 105 lung cells/well. The wells
then received 100  l RPMI-FCS containing no antigen, 100  g ESAT-61-20
peptide, 100  g Ag85B240-254 peptide, or 100  l of a 1:100 dilution of Mtb
sonicate. After 18 h of incubation at 37 C, unattached cells were aspirated
from the wells and the remaining cells were lysed with distilled water. The
wells were washed again with PBS containing 0.05% Tween 20 and incu-
bated with a second biotinylated rat anti–mouse IFN-  mAb. The wells
were then washed with PBS–Tween 20, incubated for 1 h with streptavidin-
alkaline phosphatase, washed, and developed with 3-amino-9-ethyl-carbazol
as substrate. After washing and drying, the nitrocellulose well bottoms were
punched onto a transparent adhesive film, and the number of spots per well
was counted with the aid of a microscope at 40 . The number of cells spe-
cific for each antigen preparation was calculated by subtracting the number
of spots that formed in the absence of added antigen from the number that
formed in its presence. Each experiment was repeated twice.
Flow cytometry.  Lung cells were prepared and admixed with BM-
derived DCs at a ratio of 5:1 lung cells/DC, suspended in RPMI-FCS in
two 5-ml tubes at 5   107 cells/ml, and incubated in the presence of brefel-
din A (Epicenter Technologies) at a concentration of 10  g/ml for 5 h at
37 C. The cells in one tube were washed and resuspended in medium con-
taining FITC–anti-CD3, R-phycoerthrin–anti-CD4, and Peridinin chloro-
phyll protein–anti-CD8 mAbs. The cells in the other tube were washed and
suspended in medium containing Peridinin chlorophyll protein–conju-
gated anti-CD4, R-phycoerthrin–anti-CD44, and FITC–anti-CD62L mAbs.
Anti–mouse CD16/CD32 was added to block nonspecific binding, and the
cells were incubated for 1 h at 4 C. They were then washed and fixed over-
night in 0.5% paraformaldehyde, washed again, and stained for intracellular
IFN-  with allophycocyanin–anti–IFN-  mAb. This involved treating the
cells with 0.1% saponin (Sigma-Aldrich) in PBS, and then incubating them
with allophycocyanin–anti–IFN-  mAb. All monoclonal reagents were pur-
chased from BD Biosciences. After washing, the cells were subjected to anal-
ysis with a flow cytometer (model FACSCalibur; BD Biosciences) using
FloJo software (Tree Star).
Real-time RT-PCR quantification of mRNA synthesis for IFN- 
and NOS2.  The real-time RT-PCR procedure used has been described
in detail elsewhere (26). Lungs were harvested at the times indicated in
Results, and snap frozen in liquid nitrogen. RNA extraction, clean-up,
and quantification were performed as previously described (26). In brief,
to make standard curves for IFN- , NOS2, IL-2, TNF- , IP-10, and
MCP-1, a T7 transcript of each was generated (MEGAshortscript T7 Kit;
Ambion), 10-fold serially diluted from 108 to 102 according to transcript
copy number, and each dilution subjected to the real-time RT-PCR. The
level of expression of these genes in the lungs of primary and secondary
Mtb-infected mice was calculated according to the formula N   (Ct  
b)/m, where N is the copy number, Ct is the threshold cycle, b is the y in-
tercept, and m is the slope of the standard curve line obtained. Results
were obtained with pooled lung RNA of four mice per group per time
point. Shown are the means   SDs of four separate readings per group per
time point. The experiment was performed twice with essentially the
same result.JEM VOL. 201, June 20, 2005 1923
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Immunocytochemistry.  Lungs were fixed by an intratrachial infusion of
zinc chloride/zinc acetate fixative (BD Biosciences) and an immersion in
the fixative for 24 h at room temperature. The lungs were then dehydrated
in 70 and 100% ethanol and embedded in wax according to standard proce-
dures. 6- m sections were cut with a rotary microtome and, after dewax-
ing, were treated with 5% BSA in PBS, washed in PBS, treated to block en-
dogenous biotin (Avidin/Biotin Blocking Kit; Vector Laboratories), and
treated with rat anti–mouse CD4 mAbs or rat isotype control IgG (BD Bio-
sciences) for 18 h at 4 C. After washing in PBS, sections were treated with
biotin-conjugated goat anti–rat IgG followed by avidin-biotinylated alka-
line phosphatase (Vectastain ABC-AP Kit; Vector Laboratories), and then
with the enzyme substrate (Vector Black; Vector Laboratories) to give a
brownish/black reaction product. After washing, the cells were stained for
acid-fast bacteria (39) and counterstained with methylene blue. Photomi-
crographs were taken with a microscope (model Microphot-Fx; Nikon)
with a digital camera (model Spot RT; Diagnostic Instruments).
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